Loading...
By Kelly Young
Edited by Susan Sadoughi, MD, and André Sofair, MD, MPH
The FDA has added a new indication to evolocumab (Repatha). The PCSK9 inhibitor is now approved to prevent cardiovascular events (e.g., myocardial infarction, stroke, coronary revascularization) in patients with existing cardiovascular disease, the manufacturer announced.
In a clinical trial, patients with atherosclerotic cardiovascular disease and LDL levels at or above 70 mg/dL who were given evolocumab had a significantly lower rate of the composite endpoint of CV death, MI, stroke, hospitalization for unstable angina, and coronary revascularization, compared with patients given placebo after 2 years' follow-up (9.8% vs. 11.3%).
The injectable drug, which lowers LDL cholesterol, was previously approved for use in adults with heterozygous familial hypercholesterolemia, homozygous familial hypercholesterolemia, or clinical atherosclerotic cardiovascular disease whose LDL levels were still high despite other treatments.
Dr. Harlan Krumholz, editor-in-chief of NEJM Journal Watch Cardiology, comments: "This decision was widely anticipated and allows promotional activity; but the debate continues about the role of this drug, its value in our armamentarium, and the role insurers should be playing in impeding or facilitating adoption."
Comment
LINK(S):
Manufacturer's news release (Free)
Background: NEJM Journal Watch Cardiology coverage of FOURIER study on evolocumab and cardiovascular events (Free)